Evolution of the Average Target: Rani Therapeutics Holdings, Inc.

Evolution of the Average Target - Rani Therapeutics Holdings, Inc.

Evolution of the Target Price: Rani Therapeutics Holdings, Inc.

Evolution of the Target Price - Rani Therapeutics Holdings, Inc.

Changes in Analyst Recommendations: Rani Therapeutics Holdings, Inc.

bb9901139ec.Kte57IDyGkmHpKs-JkjMJnbNF7weEfFktCpsCH49ESY.fpLjvK2xVyTQ9fFqSS2NdjCCdP1fQMUn83wiXCdqSUwaoImmssIpJcLVyA~4c2d4dc076220de349a0972731a982b2
08-18 Chardan Initiates Rani Therapeutics Holdings at Buy With $6 Price Target MT
25-10-20 Maxim Adjusts Rani Therapeutics Price Target to $10 From $5, Maintains Buy Rating MT
25-10-17 Top Midday Gainers MT
25-05-16 Oppenheimer Adjusts Rani Therapeutics Price Target to $4 From $14, Maintains Outperform Rating MT
24-08-02 Oppenheimer Initiates Rani Therapeutics Holdings at Outperform With $17 Price Target MT
24-06-14 Maxim Starts Coverage on Rani Therapeutics With Buy Rating, $15 Price Target MT
24-05-16 UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating MT
24-05-07 HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating MT
24-03-27 Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating MT
24-03-25 HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating MT
23-11-10 Wedbush Cuts Rani Therapeutics Holdings' PT to $8 From $20, Keeps Outperform Rating MT
23-11-09 HC Wainwright Adjusts Price Target on Rani Therapeutics to $16 From $20, Maintains Buy Rating MT
23-08-14 HC Wainwright Adjusts Price Target on Rani Therapeutics to $20 From $22, Keeps Buy Rating MT
22-12-07 Wedbush Lifts Rani Therapeutics Holdings' Price Target to $20 From $19, Keeps Outperform Rating MT
22-10-11 UBS Initiates Coverage on Rani Therapeutics With Buy Rating, $15 Price Target MT
22-09-29 Wedbush Adjusts Rani Therapeutics Holdings Price Target to $19 From $17, Maintains Outperform Rating MT
22-08-12 Wedbush Adjusts Price Target on Rani Therapeutics Holdings to $17 From $28, Keeps Outperform Rating MT
22-07-27 HC Wainwright Initiates Rani Therapeutics Holdings at Buy With $22 Price Target MT
22-06-13 Wedbush Starts Rani Therapeutics Holdings at Outperform With $28 Price Target MT
21-08-25 Rani Therapeutics : Canaccord Genuity Starts Rani Therapeutics Holdings at Buy With $29 Price Target MT
21-08-25 Rani Therapeutics : BTIG Starts Rani Therapeutics Holdings at Buy With $24 Price Target MT
21-08-24 Rani Therapeutics : Cantor Fitzgerald Starts Rani Therapeutics Holdings at Overweight with $23 Price Target MT
21-08-24 Rani Therapeutics : Stifel Starts Rani Therapeutics Holdings at Buy with $24 Price Target MT
21-08-24 Rani Therapeutics : BofA Securities Starts Rani Therapeutics Holdings at Buy with $23 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+1,125.32%
+35.78%
+28.93%
+10.89%
+8.75%
+14.18%
+37.21%
+37.85%
+32.7%
+4.59%
Average +133.62%
Weighted average by Cap. +24.02%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.6059USD
Average target price
7.200USD
Spread / Average Target
+1,088.31%
High Price Target
11.00USD
Spread / Highest target
+1,715.48%
Low Price Target
5.000USD
Spread / Lowest Target
+725.22%

Analyst Consensus Detail

Analyst consensus - Rani Therapeutics Holdings, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Rani Therapeutics Holdings, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rani Therapeutics Holdings, Inc.
  1. Stock Market
  2. Stocks
  3. RANI Stock
  4. Consensus Rani Therapeutics Holdings, Inc.